Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Revenue (2018 - 2023)

Denali Therapeutics (DNLI) has disclosed Revenue for 6 consecutive years, with $1.3 million as the latest value for Q3 2023.

  • Quarterly Revenue fell 64.4% to $1.3 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Jun 2024, down 99.63% year-over-year, with the annual reading at $330.5 million for FY2023, 204.74% up from the prior year.
  • Revenue for Q3 2023 was $1.3 million at Denali Therapeutics, down from $294.1 million in the prior quarter.
  • The five-year high for Revenue was $294.1 million in Q2 2023, with the low at $1000.0 in Q1 2021.
  • Average Revenue over 5 years is $29.1 million, with a median of $5.3 million recorded in 2021.
  • The sharpest move saw Revenue crashed 99.97% in 2021, then surged 4214000.0% in 2022.
  • Over 5 years, Revenue stood at $4.7 million in 2019, then skyrocketed by 101.05% to $9.4 million in 2020, then crashed by 43.73% to $5.3 million in 2021, then skyrocketed by 89.21% to $10.0 million in 2022, then crashed by 87.33% to $1.3 million in 2023.
  • According to Business Quant data, Revenue over the past three periods came in at $1.3 million, $294.1 million, and $35.1 million for Q3 2023, Q2 2023, and Q1 2023 respectively.